BMS Tests Virtual R&D Network In China For Orencia Deal With Simcere
This article was originally published in The Pink Sheet Daily
Executive Summary
BMS has been trying since 2012 to figure out a way to bring its first biologic product to China. Now, the company will partner with Simcere to hasten development of its $1.2 billion rheumatoid arthritis blockbuster Orencia.